<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28472101</article-id><article-id pub-id-type="pmc">5417515</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0176446</article-id><article-id pub-id-type="publisher-id">PONE-D-16-48612</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological Tissue</subject><subj-group><subject>Adipose Tissue</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological Tissue</subject><subj-group><subject>Adipose Tissue</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Diabetic Endocrinology</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Hormones</subject><subj-group><subject>Insulin</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Hormones</subject><subj-group><subject>Estrogens</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Menopause</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Menopause</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Menopause</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Reactions</subject><subj-group><subject>Hydrolysis</subject><subj-group><subject>Lipolysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Polymer chemistry</subject><subj-group><subject>Monomers (Chemistry)</subject><subj-group><subject>Glycerol</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Connective Tissue Cells</subject><subj-group><subject>Adipocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological Tissue</subject><subj-group><subject>Connective Tissue</subject><subj-group><subject>Connective Tissue Cells</subject><subj-group><subject>Adipocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Biological Tissue</subject><subj-group><subject>Connective Tissue</subject><subj-group><subject>Connective Tissue Cells</subject><subj-group><subject>Adipocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Musculoskeletal System</subject><subj-group><subject>Muscles</subject><subj-group><subject>Skeletal Muscles</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Musculoskeletal System</subject><subj-group><subject>Muscles</subject><subj-group><subject>Skeletal Muscles</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Estradiol-mediated improvements in adipose tissue insulin sensitivity are related to the balance of adipose tissue estrogen receptor &#x003b1; and &#x003b2; in postmenopausal women</article-title><alt-title alt-title-type="running-head">Adipose tissue estrogen receptors after menopause</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Park</surname><given-names>Young-Min</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Rocio I.</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Erickson</surname><given-names>Christopher B.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Swibas</surname><given-names>Tracy A.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cox-York</surname><given-names>Kimberly A.</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Van Pelt</surname><given-names>Rachael E.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Medicine, Division of Geriatric Medicine University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Department of Medicine, Division of Endocrinology, Diabetes and Metabolism University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Denver Health and Hospital Authority, Denver, CO, United States of America</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Department of Nutrition, Colorado State University, Fort Collins, CO, United States of America</addr-line></aff><aff id="aff005"><label>5</label><addr-line>VA Eastern Colorado Health Care System, Geriatric Research Education and Clinical Center (GRECC), Denver, CO, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Cignarella</surname><given-names>Andrea</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Universita degli Studi di Padova, ITALY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> RV.</p></list-item><list-item><p><bold>Data curation:</bold> YP RV.</p></list-item><list-item><p><bold>Formal analysis:</bold> YP RV.</p></list-item><list-item><p><bold>Funding acquisition:</bold> RV.</p></list-item><list-item><p><bold>Investigation:</bold> YP RP CE TS KC RV.</p></list-item><list-item><p><bold>Methodology:</bold> YP RV.</p></list-item><list-item><p><bold>Project administration:</bold> RV.</p></list-item><list-item><p><bold>Resources:</bold> RV.</p></list-item><list-item><p><bold>Software:</bold> RV.</p></list-item><list-item><p><bold>Supervision:</bold> RV.</p></list-item><list-item><p><bold>Validation:</bold> RV KC.</p></list-item><list-item><p><bold>Visualization:</bold> YP RV.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> YP RV.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> YP RP CE TS KC RV.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>rachael.vanpelt@ucdenver.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>4</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>5</issue><elocation-id>e0176446</elocation-id><history><date date-type="received"><day>9</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Park et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Park et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0176446.pdf"/><abstract><p>We recently demonstrated that short-term estradiol (E<sub>2</sub>) treatment improved insulin-mediated suppression of lipolysis in postmenopausal women, but to a greater extent in those who were late compared to early postmenopausal. In this follow-up study we tested whether subcutaneous adipose tissue (SAT) expression of estrogen receptors (ER) &#x003b1; and &#x003b2; differs between early and late postmenopausal women. We further tested whether the balance of ER&#x003b1; to ER&#x003b2; in SAT determined the effect of E<sub>2</sub> on SAT insulin sensitivity. The present study included 35 women who were &#x02264;6 years past menopause (EPM; n = 16) or &#x02265;10 years past menopause (LPM; n = 19). Fasted SAT samples were taken following 1-week transdermal E<sub>2</sub> treatment or placebo (PL) in a random cross-over design. Samples were analyzed for nuclear/cytosolic protein content and mRNA expression using Western blot and qPCR, respectively. While ESR1 increased slightly (~1.4-fold) following E<sub>2</sub> treatment in both groups, ER&#x003b1; and ER&#x003b2; protein expression did not differ between groups at baseline or in response to E<sub>2</sub>. However, the balance of ER&#x003b1;/ER&#x003b2; protein in the SAT nuclear fraction increased 10% in EPM compared to a 25% decrease in LPM women (group x treatment interaction, <italic>p</italic>&#x0003c;0.05). A greater proportion of ER&#x003b1;/ER&#x003b2; protein in the nuclear fraction of SAT at baseline (placebo day) was associated with greater reduction in SAT insulin resistance (i.e., better suppression of lipolysis, EC<sub>50</sub>) in response to E<sub>2</sub> (r = -0.431, <italic>p</italic>&#x0003c;0.05). In conclusion, there do not appear to be differences in the proportion of adipose tissue ER&#x003b1;/ER&#x003b2; protein in late, compared to early, postmenopausal women. However, the balance of ER&#x003b1;/ER&#x003b2; may be important for E<sub>2</sub>-mediated improvement in adipose tissue insulin sensitivity.</p><p><bold>Trial Registration: Clinical Trials#:</bold>
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01605071">NCT01605071</ext-link></p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 DK088105</award-id><principal-award-recipient><name><surname>Van Pelt</surname><given-names>Rachael E.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P50 HD073063</award-id><principal-award-recipient><name><surname>Van Pelt</surname><given-names>Rachael E.</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32 DK007446</award-id><principal-award-recipient><name><surname>Cox-York</surname><given-names>Kimberly A.</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30 DK048520</award-id><principal-award-recipient><name><surname>Van Pelt</surname><given-names>Rachael E.</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>UL1 TR001082</award-id><principal-award-recipient><name><surname>Van Pelt</surname><given-names>Rachael E.</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by the National Institutes of Health: R01 DK088105, P50 HD073063, P30 DK048520, UL1 TR001082; all to RV; T32 DK007446 to KC.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All of the relevant data (i.e. outcomes and blot images) are available from the Dryad Digital Repository: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.bq124">http://dx.doi.org/10.5061/dryad.bq124</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All of the relevant data (i.e. outcomes and blot images) are available from the Dryad Digital Repository: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.bq124">http://dx.doi.org/10.5061/dryad.bq124</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Loss of ovarian hormones and prolonged estrogen deficiency after menopause puts women at risk of metabolic dysregulation, increasing obesity and type 2 diabetes [<xref rid="pone.0176446.ref001" ref-type="bibr">1</xref>]. Exogenous treatment with estrogen-based hormone therapy reduces incidence of new onset diabetes in postmenopausal women [<xref rid="pone.0176446.ref002" ref-type="bibr">2</xref>], but whether this benefit is through improvements in insulin sensitivity remains unclear. We previously demonstrated that both conjugated estrogens and estradiol (E<sub>2</sub>) acutely improve insulin-mediated glucose disposal (i.e., skeletal muscle insulin sensitivity) in postmenopausal women, but only when treatment is initiated early in menopause [<xref rid="pone.0176446.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>]. Compared to early postmenopausal women, late postmenopausal women had a reduced glucose disposal after E<sub>2</sub> treatment [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>], supporting the concept that timing of estrogen after menopause may determine benefit versus harm for this outcome. On the other hand, insulin-mediated suppression of lipolysis (i.e., adipose tissue insulin sensitivity) was improved in both early and late postmenopausal women, suggesting benefit irrespective of time since menopause for this outcome [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>]. Indeed, E<sub>2</sub> improved adipose tissue insulin sensitivity to a greater extent in late compared to early postmenopausal women. The mechanism for such timing- and tissue-specific differences in E<sub>2</sub> action is not known, but may be partly due to changes in estrogen receptor (ER) expression.</p><p>E<sub>2</sub> exerts its biologic actions via two ER subtypes, ER&#x003b1; and ER&#x003b2; [<xref rid="pone.0176446.ref006" ref-type="bibr">6</xref>]. Pre-clinical ER knockout models suggests that ER&#x003b1;, but not ER&#x003b2;, is positively related to insulin-mediated glucose disposal and insulin signaling [<xref rid="pone.0176446.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0176446.ref008" ref-type="bibr">8</xref>]. Moreover, the overall balance of ER&#x003b1; relative to ER&#x003b2; within a tissue is thought to be important to the action of E<sub>2</sub> on insulin sensitivity [<xref rid="pone.0176446.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0176446.ref010" ref-type="bibr">10</xref>]. It is not yet known whether the balance of ER&#x003b1; to ER&#x003b2; changes with increasing age or time since menopause and in a tissue-specific manner. We recently observed a reduced skeletal muscle ER&#x003b1; and ER&#x003b2; nuclear protein in late, compared to early, postmenopausal women [<xref rid="pone.0176446.ref011" ref-type="bibr">11</xref>]. We hypothesized there would be similar reductions in adipose tissue ER&#x003b1; and ER&#x003b2; with increasing time since menopause from these same women. We further hypothesized that the balance of ER&#x003b1;/ER&#x003b2; in adipose tissue would be associated with insulin sensitivity and response to E<sub>2</sub> in that tissue.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Subjects</title><p>The present study analyzed subcutaneous adipose tissue (SAT) samples from a subset of postmenopausal women who participated in a previous study [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>]; samples were obtained from 35 women who were &#x02264;6 years past menopause (EPM; n = 16) or &#x02265;10 years past menopause (LPM; n = 19). Detailed inclusion and exclusion criteria were previously described [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>]. Briefly, participants were healthy, non-obese (BMI&#x0003c;30kg/m<sup>2</sup>), sedentary to moderately active, postmenopausal women (age 45&#x02013;70 yr) who had not used any estrogen-based hormone therapy. All participants provided informed consent before enrollment. This protocol was approved by the Colorado Multiple Institutional Review Board (COMIRB #11&#x02013;0788).</p></sec><sec id="sec004"><title>Study design</title><p>At the first visit, oral glucose tolerance, physical activity, and body composition were assessed. All participants underwent two treatment conditions (i.e., 1 week of transdermal estradiol [E<sub>2</sub>] or placebo [PL]) in a random order with a washout period (6 &#x000b1; 2 wks) between study visits. On both visits, following an overnight fast, SAT was biopsied prior to insulin sensitivity assessments using hyperinsulinemic-euglycemic clamp.</p></sec><sec id="sec005"><title>Body composition and glucose tolerance measurement</title><p>At the screening visit, fat-free mass (FFM) and total fat mass (FM) were determined by a dual x-ray absorptiometry (DXA, Hologic Discovery W, software version 11.2) as previously reported [<xref rid="pone.0176446.ref012" ref-type="bibr">12</xref>]. A 2hr 75g oral glucose tolerance test (OGTT) was employed in the morning following an overnight fast as previously described [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>]. Circulating glucose and insulin responses over the 2hr period were measured; area under the curve (AUC) calculated using the trapezoidal method.</p></sec><sec id="sec006"><title>Dietary lead-in period</title><p>All participants were required to maintain their body weight within &#x000b1;2kg throughout testing. To control energy intake among the participants in the days prior to the testing day, a standardized diet was provided by the University of Colorado Anschutz Medical Campus (UC-AMC) Clinical Translational Research Center (CTRC) metabolic kitchen 3 days prior to each clamp study visit as previously described [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>].</p></sec><sec id="sec007"><title>Estradiol or placebo treatment</title><p>The clamp study visit was repeated following 1 week of transdermal E<sub>2</sub> (0.15mg) and following matching transdermal placebo treatment in a blinded, randomized, and cross-over design.</p></sec><sec id="sec008"><title>Hyperinsulinemic-euglycemic clamp</title><p>Under the two separate treatment conditions, participants completed a 2-stage (4 and 40 mU/m<sup>2</sup>/min) hyperinsulinemic-euglycemic clamp to assess insulin-stimulated glucose disposal rate (GDR) and suppression of lipolysis (EC<sub>50</sub>) as previously described [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>]. In brief, GDR was calculated from the steady-state glucose infusion rate required to maintain euglycemia (~90mg/dL) during a 40mU/m<sup>2</sup>/min insulin infusion. EC<sub>50</sub>, or the insulin concentration to half-maximally suppress glycerol, was calculated from the exponential decay curves for glycerol across the basal and insulin stages of the clamp as previously described [<xref rid="pone.0176446.ref013" ref-type="bibr">13</xref>]. Plasma samples collected during the clamp visits were stored at -80&#x000b0;C; and analyzed for circulating glucose, insulin, and glycerol in batch by the UC-AMC CTRC laboratory.</p></sec><sec id="sec009"><title>Human adipose tissue biopsies</title><p>On the morning prior to each clamp, SAT samples were collected from the lateral thigh region in the fasted state using a mini-liposuction technique as previously described [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>]. Collected SAT was rinsed with sterile saline, separated from the fluid and immediately flash frozen in liquid N<sub>2</sub> for later analyses.</p></sec><sec id="sec010"><title>Adipocyte size and distribution</title><p>Immediately after collection, 50 mg of fresh SAT was used to determine adipocyte cell size (mean cell diameter) and size frequency distribution with Cell Counting Analysis Program (CCAP; Mayo Clinic, Rochester, MN) as previously described [<xref rid="pone.0176446.ref014" ref-type="bibr">14</xref>]. The relative proportion of small (20&#x02013;60&#x003bc;), medium (60&#x02013;100&#x003bc;), and large (100&#x02013;140&#x003bc;) adipocytes with and without treatment with 1 week of E<sub>2</sub> are reported for each group.</p></sec><sec id="sec011"><title>mRNA quantification (RT-PCR)</title><p>Total RNA was extracted from SAT samples collected using the RNeasy Lipid Mini Kit (Qiagen Inc.). RNA was 1) analyzed and quantitated using Nanodrop 2000c (ThermoFisher Scientific, Waltham, MA); 2) reverse transcribed using Verso cDNA synthesis kit (ThermoFisher Scientific, Waltham, MA), and 3) analyzed by qPCR in duplicate using TaqMan&#x000ae; Fast Advanced Mastermix (ThermoFisher Scientific, Waltham, MA) on an 7900HT Fast Real-Time PCR System (ThermoFisher Scientific, Waltham, MA) along with a no-template control per gene. Reference gene TATAA-box binding protein (TBP) was used as endogenous control (overall standard deviation 0.54). The Taqman primer/probes sets (Applied Biosystems, Foster, CA) used were: ESR1 (ER&#x003b1;, Hs00174860_m1), ESR2 (ER&#x003b2;, Hs00230957_m1); and TBP Hs00427620_m1. Baseline mRNA expression was determined by calculating 2<sup>-&#x00394;Ct</sup> for each sample relative to the within group mean and normalized to the reference gene. The 2<sup>-&#x00394;&#x00394;Ct</sup> method was used to determine fold-changes from the placebo condition to the E<sub>2</sub> condition as previously described [<xref rid="pone.0176446.ref015" ref-type="bibr">15</xref>].</p></sec><sec id="sec012"><title>Cellular protein fractionation</title><p>The protocol for protein fractionation was adapted from previous research [<xref rid="pone.0176446.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0176446.ref016" ref-type="bibr">16</xref>]. Approximately 200mg AT was pulverized and homogenized in cold Buffer A containing 50mM NaF, 20mM HEPES, 100mM NaCl, 1mM ethyleneglycol tetraacetic acid (EGTA), 1mM ethylenediamine tetraacetic acid (EDTA), 1mM dithiothreitol (DTT), 2mM 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 1mM sodium orthovanadate, 20&#x003bc;g/ml aprotinin, 20&#x003bc;g/ml leupeptin, 20&#x003bc;g/ml antipain, 5mM <italic>p</italic>-chloromercuri phenylsulfonate, and 10mM iodoacetamide. Samples were centrifuged at 500g at 4&#x000b0;C for 5 min, and the supernatant (cytosolic fraction) stored at 80&#x000b0;C. Pellets (crude nuclei) were re-suspended and sonicated in cold Buffer B (Buffer A plus 400mM NaCl, 25% glycerol, and 0.1% sodium dodecyl sulfate [SDS]), incubated at room temperature for 15 min, then centrifuged at 3,000g at 4&#x000b0;C for 5 min; and the supernatant (nuclear fraction) stored at -80&#x000b0;C for later protein assessment.</p></sec><sec id="sec013"><title>SDS-PAGE western blot</title><p>Protein concentrations in nuclear and cytosolic fraction were measured using the Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL). Samples containing the homogenates (30 &#x003bc;g of protein) and laemmli buffer were separated by 8% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes. Membranes were probed with primary antibodies (1:200&#x02013;1,000 concentrations). ER&#x003b1; and ER&#x003b2; antibodies were obtained from Cell Signaling (cs8644, Beverly, MA) and R&#x00026;D systems (mab7106, Minneapolis, MN), respectively. Evidence of correct band detection for ER&#x003b1; and ER&#x003b2; was shown in <xref ref-type="fig" rid="pone.0176446.g001">Fig 1</xref>. Individual protein bands were quantified using a densitometer (Bio-Rad Laboratories, Hercules, CA), and normalized to &#x003b2;-actin (loading control, #4967, Cell Signaling, Beverly, MA). Protein content was expressed relative to the early postmenopausal group placebo-treated condition. We confirmed that the results did not differ with and without this normalization step.</p><fig id="pone.0176446.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0176446.g001</object-id><label>Fig 1</label><caption><title>Evidence of correct western band detection for estrogen receptors (ER), the purity of nuclear fraction, and representative images.</title><p>(A) ER&#x003b1; and &#x003b2; protein bands in nuclear and cytosolic fraction, Lane .1: positive control (MCF7), Lane 2: negative control (MDA-MB-231) or empty well (loading buffer only), Lane 3: 30ug protein from adipose tissue; (B) the purity of nuclear fraction, Lane 1: nuclear fraction, Lane 2: cytosolic fraction. &#x003b1;Tubulin was used as a cytosolic marker; no bands were detected in nuclear fraction; (C) representative images of ER&#x003b1; and &#x003b2; protein bands in nuclear and cytosolic fraction.</p></caption><graphic xlink:href="pone.0176446.g001"/></fig></sec><sec id="sec014"><title>Statistical analysis</title><p>The present study employed a two-group repeated measure design to test for main effects of group (EPM vs. LPM) or treatment (PL vs. E<sub>2</sub>) and group x treatment interactions. When a significant group x treatment interaction was found, <italic>post hoc</italic> tests were used for pair-wise comparisons. Pearson correlations were used to determine the associations between SAT proteins and insulin sensitivity (EC<sub>50</sub>). Baseline group differences (LPM vs. EPM) in descriptive outcomes were assessed by independent <italic>t</italic> tests. All data were analyzed using SPSS Statistics version 24.0 (IBM Corp., New York, NY). Data are reported as mean &#x000b1; SEM unless otherwise specified. Level of significance was set at <italic>P</italic>&#x0003c;0.05.</p></sec></sec><sec sec-type="results" id="sec015"><title>Results</title><sec id="sec016"><title>Subject characteristics</title><p>Full descriptive characteristics for women (n = 24/group) enrolled in the parent study were previously published [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>]; the subset of women (n = 16-19/group) for whom we had sufficient SAT are reported herein. As reported for the full cohort, LPM women in this subset were on average 7 years older and 9 years further past menopause compared to EPM (<xref ref-type="table" rid="pone.0176446.t001">Table 1</xref>). LPM women had less total fat and fat-free mass, but percent fat did not differ from EPM women. All women had normal fasting and post-challenge (i.e. OGTT) glucose and insulin concentrations (<xref ref-type="table" rid="pone.0176446.t001">Table 1</xref>). Circulating E<sub>2</sub>, estrone, sex hormone-binding globulin (SHBG), leptin, and glycerol increased in response to E<sub>2</sub> treatment (<xref ref-type="table" rid="pone.0176446.t002">Table 2</xref>). Consistent with the parent study [<xref rid="pone.0176446.ref005" ref-type="bibr">5</xref>], EC<sub>50</sub> was reduced in both groups (i.e., increased SAT insulin sensitivity) but to a greater extent in LPM (<italic>P</italic> = 0.018; <xref ref-type="table" rid="pone.0176446.t002">Table 2</xref>).</p><table-wrap id="pone.0176446.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0176446.t001</object-id><label>Table 1</label><caption><title>Subject characteristics.</title></caption><alternatives><graphic id="pone.0176446.t001g" xlink:href="pone.0176446.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" style="border-bottom:thick" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">EPM</th><th align="center" rowspan="1" colspan="1">LPM</th></tr><tr><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">n = 16</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">n = 19</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (yr)</td><td align="center" rowspan="1" colspan="1">56 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">63 &#x000b1; 3<xref ref-type="table-fn" rid="t001fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Time since menopause (yr)</td><td align="center" rowspan="1" colspan="1">3 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">12 &#x000b1; 2<xref ref-type="table-fn" rid="t001fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">70.5 &#x000b1; 7.7</td><td align="center" rowspan="1" colspan="1">63.3 &#x000b1; 8.0<xref ref-type="table-fn" rid="t001fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">26.1 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">23.9 &#x000b1; 3.3<xref ref-type="table-fn" rid="t001fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Total fat mass (kg)</td><td align="center" rowspan="1" colspan="1">26.3 &#x000b1; 6.2</td><td align="center" rowspan="1" colspan="1">22.5 &#x000b1; 6.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Fat-free mass (kg)</td><td align="center" rowspan="1" colspan="1">44.3 &#x000b1; 4.0</td><td align="center" rowspan="1" colspan="1">40.8 &#x000b1; 3.7<xref ref-type="table-fn" rid="t001fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">%Fat</td><td align="center" rowspan="1" colspan="1">36.9 &#x000b1; 5.4</td><td align="center" rowspan="1" colspan="1">34.9 &#x000b1; 6.2</td></tr><tr><td align="left" rowspan="1" colspan="1">OGTT glucose AUC (*10<sup>4</sup>)</td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1; 0.2</td><td align="center" rowspan="1" colspan="1">1.4 &#x000b1; 0.3<xref ref-type="table-fn" rid="t001fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">OGTT insulin AUC (*10<sup>3</sup>)</td><td align="center" rowspan="1" colspan="1">6.7 &#x000b1; 3.9</td><td align="center" rowspan="1" colspan="1">6.3 &#x000b1; 2.2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>mean&#x000b1;SD</p></fn><fn id="t001fn002"><p>*<italic>p</italic>&#x0003c;0.05 group difference; EPM, early (&#x02264;6yr) postmenopausal; LPM, late (&#x02265;10yr) postmenopausal; BMI, body mass index; OGTT, 2hr oral glucose tolerance test; AUC, area under the curve.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0176446.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0176446.t002</object-id><label>Table 2</label><caption><title>Treatment-associated changes in circulating hormones and metabolic markers.</title></caption><alternatives><graphic id="pone.0176446.t002g" xlink:href="pone.0176446.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" style="border-bottom:thick" colspan="1"/><th align="center" colspan="2" rowspan="1">EPM</th><th align="center" colspan="2" rowspan="1">LPM</th><th align="center" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">Treatment<break/>x Group</th></tr><tr><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">PL</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">E<sub>2</sub></th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">PL</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">E<sub>2</sub></th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1"><italic>p</italic>-value</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Baseline fasting</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;E<sub>2</sub> (pg/mL)</td><td align="center" rowspan="1" colspan="1">16 &#x000b1; 17</td><td align="center" rowspan="1" colspan="1">179 &#x000b1; 102</td><td align="center" rowspan="1" colspan="1">10 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">149 &#x000b1; 56</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Estrone (pg/mL)</td><td align="center" rowspan="1" colspan="1">30 &#x000b1; 15</td><td align="center" rowspan="1" colspan="1">116 &#x000b1; 49</td><td align="center" rowspan="1" colspan="1">29 &#x000b1; 16</td><td align="center" rowspan="1" colspan="1">105 &#x000b1; 48</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;SHBG (nM/L)</td><td align="center" rowspan="1" colspan="1">42 &#x000b1; 20</td><td align="center" rowspan="1" colspan="1">53 &#x000b1; 19</td><td align="center" rowspan="1" colspan="1">57 &#x000b1; 25</td><td align="center" rowspan="1" colspan="1">70 &#x000b1; 31</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Leptin (ng/mL)</td><td align="center" rowspan="1" colspan="1">19 &#x000b1; 13</td><td align="center" rowspan="1" colspan="1">21 &#x000b1; 15</td><td align="center" rowspan="1" colspan="1">15 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 12</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">90 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">89 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">89 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">88 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">ns</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Insulin (uU/mL)</td><td align="center" rowspan="1" colspan="1">8.3 &#x000b1; 2.1</td><td align="center" rowspan="1" colspan="1">7.6 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">8.7 &#x000b1; 5.4</td><td align="center" rowspan="1" colspan="1">7.8 &#x000b1; 3.5</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Glycerol (mg/dL)</td><td align="center" rowspan="1" colspan="1">121 &#x000b1; 47</td><td align="center" rowspan="1" colspan="1">105 &#x000b1; 32</td><td align="center" rowspan="1" colspan="1">131 &#x000b1; 37</td><td align="center" rowspan="1" colspan="1">116 &#x000b1; 36</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;FFA (umol/L)</td><td align="center" rowspan="1" colspan="1">656 &#x000b1; 161</td><td align="center" rowspan="1" colspan="1">659 &#x000b1; 135</td><td align="center" rowspan="1" colspan="1">793 &#x000b1; 222</td><td align="center" rowspan="1" colspan="1">772 &#x000b1; 182</td><td align="center" rowspan="1" colspan="1">ns</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" colspan="3" rowspan="1">During clamp (40uU/m<sup>2</sup>/min)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">85 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">88 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">88 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">86 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">ns</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Insulin (uU/mL)</td><td align="center" rowspan="1" colspan="1">91 &#x000b1; 21</td><td align="center" rowspan="1" colspan="1">77 &#x000b1; 16</td><td align="center" rowspan="1" colspan="1">95 &#x000b1; 24</td><td align="center" rowspan="1" colspan="1">84 &#x000b1; 24</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Glycerol (mg/dL)</td><td align="center" rowspan="1" colspan="1">34 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">34 &#x000b1; 13</td><td align="center" rowspan="1" colspan="1">40 &#x000b1; 14</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 8</td><td align="center" rowspan="1" colspan="1">ns</td><td align="center" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;GDR (mg/kg/min)</td><td align="center" rowspan="1" colspan="1">7.2 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">7.3 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">7.2 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">6.7 &#x000b1; 2.1</td><td align="center" rowspan="1" colspan="1">ns</td><td align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;GDR (mg/kgFFM/min)</td><td align="center" rowspan="1" colspan="1">11.5 &#x000b1; 2.8</td><td align="center" rowspan="1" colspan="1">11.7 &#x000b1; 3.0</td><td align="center" rowspan="1" colspan="1">11.2 &#x000b1; 3.0</td><td align="center" rowspan="1" colspan="1">10.3 &#x000b1; 2.8</td><td align="center" rowspan="1" colspan="1">ns</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;EC<sub>50</sub> (uU/mL)</td><td align="center" rowspan="1" colspan="1">11.5 &#x000b1; 2.1</td><td align="center" rowspan="1" colspan="1">10.6 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">14.1 &#x000b1; 5.4</td><td align="center" rowspan="1" colspan="1">11.0 &#x000b1; 3.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">0.018</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>mean&#x000b1;SD; EPM, early (&#x02264;6yr) postmenopausal; LPM, late (&#x02265;10yr) postmenopausal; PL, placebo; E<sub>2</sub>, estradiol; SHBG, sex hormone-binding globulin; FFA, free fatty acid; GDR, glucose disposal rate during clamp; FFM, fat free mass; EC<sub>50</sub>, insulin suppression of lipolysis (insulin concentration needed to half-maximally suppress glycerol).</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec017"><title>Adipocyte morphology</title><p>The proportion of small, medium, and large adipocytes over whole adipocytes, and the average diameter of whole adipocytes were not statistically different between groups. However, there was a non-significant trend for the proportion of small adipocytes to be decreased (<italic>P</italic> = 0.11; <xref ref-type="fig" rid="pone.0176446.g002">Fig 2B</xref>) and the average diameter of adipocytes to be increased (<italic>P</italic> = 0.10; <xref ref-type="fig" rid="pone.0176446.g002">Fig 2B</xref>) in response to E<sub>2</sub> treatment across groups.</p><fig id="pone.0176446.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0176446.g002</object-id><label>Fig 2</label><caption><title>Adipocyte size and distribution.</title><p>(A) Representative images of isolated adipocytes each group; (B) the proportion of small (20&#x02013;60&#x003bc;), medium (60&#x02013;100&#x003bc;), and large (100&#x02013;140&#x003bc;) adipocytes; and the average diameter of whole adipocytes. Values are means&#x000b1;SE; early postmenopausal women [EPM; n = 16]; late postmenopausal women [LPM; n = 17]; treated either with placebo [PL] or estradiol [E<sub>2</sub>].</p></caption><graphic xlink:href="pone.0176446.g002"/></fig></sec><sec id="sec018"><title>Baseline (placebo) group difference</title><p>There were no group (LPM vs. EPM) differences in SAT ESR1 (ER&#x003b1;; <italic>P</italic> = 0.102) or ESR2 (ER&#x003b2;; <italic>P</italic> = 0.078; <xref ref-type="fig" rid="pone.0176446.g003">Fig 3A</xref>) gene expression. There were also no group differences in the amount of ER&#x003b1; (<xref ref-type="fig" rid="pone.0176446.g004">Fig 4A and 4B</xref>), ER&#x003b2; (<xref ref-type="fig" rid="pone.0176446.g004">Fig 4C and 4D</xref>), or the proportion of ER&#x003b1;/ER&#x003b2; (<xref ref-type="fig" rid="pone.0176446.g004">Fig 4E and 4F</xref>) protein in either the nuclear or cytosolic fractions of SAT.</p><fig id="pone.0176446.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0176446.g003</object-id><label>Fig 3</label><caption><title>Estrogen receptor (ER) gene expression.</title><p>(A) Baseline (placebo) group difference for ESR1 (ER&#x003b1;) and ESR2 (ER&#x003b2;) gene expression; (B) fold-change from placebo condition in response to 1 week of transdermal E<sub>2</sub> treatment. Values are means&#x000b1;SE; early postmenopausal women [EPM; n = 12]; late postmenopausal women [LPM; n = 16].</p></caption><graphic xlink:href="pone.0176446.g003"/></fig><fig id="pone.0176446.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0176446.g004</object-id><label>Fig 4</label><caption><title>Estrogen receptor (ER) protein content.</title><p>(A) ER&#x003b1; protein in nuclear fraction, (B) ER&#x003b1; protein in cytosolic fraction, (C) ER&#x003b2; protein in nuclear fraction, (D) ER&#x003b2; protein in cytosolic fraction, (E) ratio of ER&#x003b1;/ER&#x003b2; protein in nuclear fraction, and (F) ratio of ER&#x003b1;/ER&#x003b2; protein in cytosolic fraction. Values are means&#x000b1;SE (n = 14&#x02013;19 per group). NS = no significant difference between groups; Interaction = group-by-treatment interaction; group (early postmenopausal women [EPM] vs. late postmenopausal women [LPM]); treatment (estradiol [E<sub>2</sub>] vs. placebo [PL]). *Denotes significant (<italic>P</italic>&#x0003c;0.05) within group change in response to E<sub>2</sub> treatment</p></caption><graphic xlink:href="pone.0176446.g004"/></fig></sec><sec id="sec019"><title>Changes in response to E<sub>2</sub></title><p>Adipose tissue ESR1, but not ESR2, gene expression increased 1.4- and 1.3- fold in response to E<sub>2</sub> treatment in EPM and LPM, respectively (<xref ref-type="fig" rid="pone.0176446.g003">Fig 3B</xref>). ER&#x003b1; and ER&#x003b2; protein content in the nuclear and cytosolic fractions did not change in response to E<sub>2</sub> treatment, but the proportion of ER&#x003b1;/ER&#x003b2; in the nuclear fraction was increased in EPM and decreased in LPM (<xref ref-type="fig" rid="pone.0176446.g004">Fig 4</xref>; interaction, <italic>P</italic> = 0.04). There was no change in cytosolic ER&#x003b1;/ER&#x003b2; following E<sub>2</sub> treatment.</p></sec><sec id="sec020"><title>Correlations</title><p>The E<sub>2</sub>-mediated change in SAT insulin resistance was inversely correlated with the proportion of ER&#x003b1;/ER&#x003b2; protein in the nuclear fraction (r = -0.431, <italic>P</italic> = 0.017; <xref ref-type="fig" rid="pone.0176446.g005">Fig 5A</xref>), but not the cytosolic fraction (r = 0.118, <italic>P</italic> = 0.535; <xref ref-type="fig" rid="pone.0176446.g005">Fig 5B</xref>) at baseline (placebo day).</p><fig id="pone.0176446.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0176446.g005</object-id><label>Fig 5</label><caption><title>Estradiol (E<sub>2</sub>)-mediated change in adipose tissue insulin resistance versus the ratio of estrogen receptor (ER) &#x003b1;/&#x003b2; protein.</title><p>Association between E<sub>2</sub>-mediated change in adipose tissue insulin resistance (&#x00394;EC<sub>50</sub>) and baseline (placebo): (A) nuclear ER&#x003b1;/ER&#x003b2;; or (B) cytosolic ER&#x003b1;/ER&#x003b2;. <bold>&#x02020;</bold>Denotes a significant (<italic>P</italic>&#x0003c;0.05) correlation.</p></caption><graphic xlink:href="pone.0176446.g005"/></fig></sec></sec><sec sec-type="conclusions" id="sec021"><title>Discussion</title><p>The present study is the first to show that adipose tissue ER&#x003b1; and ER&#x003b2; protein are not reduced in late, compared to early, postmenopausal women. However, those women who had a greater proportion of ER&#x003b1;/ER&#x003b2; in adipose tissue showed a greater improvement in adipose tissue insulin sensitivity (i.e., less insulin needed to suppress lipolysis) in response to E<sub>2</sub>. While ER&#x003b1; and ER&#x003b2; protein did not change in response to 1 week of E<sub>2</sub>, the proportion of ER&#x003b1;/ER&#x003b2; increased 10% in early postmenopausal women compared to a 25% decrease in late postmenopausal women.</p><sec id="sec022"><title>Differences between adipose tissue and muscle</title><p>The results of the current studies in adipose tissue differ from our recent studies in skeletal muscle. In muscle we observed a reduction in both ER&#x003b1; and ER&#x003b2; protein in late, compared to early, postmenopausal women suggesting declines with time since menopause [<xref rid="pone.0176446.ref011" ref-type="bibr">11</xref>]. Conversely, in the present study the lack of a group difference in adipose tissue ER&#x003b1; and ER&#x003b2; suggested there may not be an inevitable decline in adipose tissue ER with increasing time since menopause. Similar to what we previously observed in muscle, 1 week of E<sub>2</sub> did not change ER protein expression in adipose tissue. However, unlike muscle, the balance of ER&#x003b1;/ER&#x003b2; in adipose tissue did appear to change in response to E<sub>2</sub>. This might suggest that longer term use of estrogens could eventually impact overall expression of ER in adipose tissue. Another difference between adipose tissue and skeletal muscle that emerged was in the association between ER expression and insulin sensitivity within that tissue. In the current study the balance of ER&#x003b1;/ER&#x003b2; in adipose tissue predicted E<sub>2</sub>-mediated changes in adipose tissue insulin sensitivity (i.e., insulin suppression of lipolysis). Whereas in skeletal muscle the prevailing balance of ER&#x003b1;/ER&#x003b2; was not predictive of E<sub>2</sub>-mediated changes in skeletal muscle insulin sensitivity (i.e., insulin stimulated glucose uptake).</p></sec><sec id="sec023"><title>Balance of estrogen receptors and tissue function</title><p>E<sub>2</sub> exerts biologic actions through two receptor sub-types, ER&#x003b1; and ER&#x003b2; [<xref rid="pone.0176446.ref006" ref-type="bibr">6</xref>]; the metabolic action of which is often opposing. Global knockout of ER&#x003b1;, but not ER&#x003b2;, leads to a metabolic syndrome phenotype (e.g., impaired glucose homeostasis, inflammation) in rodent models [<xref rid="pone.0176446.ref010" ref-type="bibr">10</xref>]. Global knockout models further suggest that E<sub>2</sub> binding to ER&#x003b1; protects against increasing adiposity, while E<sub>2</sub>-activated ER&#x003b2; appears to accelerate adiposity [<xref rid="pone.0176446.ref017" ref-type="bibr">17</xref>]. Moreover, knocking out ER&#x003b1; in adipose tissue specifically leads to adipose tissue dysfunction (i.e., inflammation and fibrosis); and in the absence of ER&#x003b1;, ER&#x003b2; appears to play a protective role [<xref rid="pone.0176446.ref018" ref-type="bibr">18</xref>]. Thus the balance of the two ER subtypes is thought to be important to adipose tissue function and metabolic phenotype.</p></sec><sec id="sec024"><title>Changes in estrogen receptor balance over time</title><p>Few studies have measured ER in human tissues, so it is not yet known whether the balance of ER&#x003b1;/ER&#x003b2; changes with age, as women transition through menopause, or with prolonged estrogen deficiency after menopause. One cross-sectional study reported that ER&#x003b2;, but not ER&#x003b1;, was higher in postmenopausal compared to premenopausal women [<xref rid="pone.0176446.ref019" ref-type="bibr">19</xref>]. In the present study we found no differences in adipose tissue ER&#x003b1; and ER&#x003b2; in late compared to early postmenopausal women. In the context of our previously observed declines in skeletal muscle ER&#x003b1; and ER&#x003b2; with increasing time since menopause, it appears that any changes in ER with aging or estrogen deficiency are likely tissue-specific. Future studies are greatly needed to examine whether the relative balance of ER&#x003b1;/ER&#x003b2; changes with aging or estrogen deficiency in other E<sub>2</sub>-sensitive tissues and cells (e.g., brain, liver, immune cells).</p></sec><sec id="sec025"><title>Estrogen receptor response to exogenous E<sub>2</sub></title><p>In the present study we observed an increase in <italic>ESR1</italic> gene expression following one week of transdermal E<sub>2</sub> in both early and late postmenopausal women; yet ER&#x003b1; protein did not change in response to E<sub>2</sub>. This discrepancy between gene expression and protein may be due to the posttranslational modification (e.g., protein degradation or ubiquitination) [<xref rid="pone.0176446.ref020" ref-type="bibr">20</xref>], resulting in no protein difference between groups shown in the present study. Despite lack of significant change in either ER&#x003b1; or ER&#x003b2; separately, there was a group-by-treatment interaction such that the balance of nuclear ER&#x003b1;/ER&#x003b2; protein increased in early but decreased in late postmenopausal women. If such acute changes in ER&#x003b1;/ER&#x003b2; persist with longer term estrogen treatment, this might prove beneficial to early postmenopausal women but harmful to late postmenopausal women. Future studies are needed to determine how long term use of estrogen-based hormone therapies impacts the balance of ER across tissues and with increasing time since menopause.</p></sec><sec id="sec026"><title>Adipose tissue estrogen receptors and insulin action</title><p>The importance of ER&#x003b1; for glucose homeostasis and skeletal muscle insulin sensitivity has been well documented in pre-clinical studies [<xref rid="pone.0176446.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0176446.ref010" ref-type="bibr">10</xref>]. By comparison little is known about the relative importance of ER for adipose tissue insulin sensitivity. Knocking out ER&#x003b1; promotes increased adiposity, possibly secondary to adipose tissue dysfunction [<xref rid="pone.0176446.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0176446.ref018" ref-type="bibr">18</xref>]. Changes in adipose tissue in response to ER&#x003b1; knockout include loss of GLUT4 (glucose transporter protein) and increased inflammation and fibrosis [<xref rid="pone.0176446.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0176446.ref021" ref-type="bibr">21</xref>]. However, to our knowledge, adipose tissue sensitivity to insulin suppression of lipolysis has not been studied in these preclinical models. In premenopausal human tissue there is evidence to suggest that E<sub>2</sub>, via ER&#x003b1;, may impact adipose tissue lipolysis via increased expression of adrenergic receptors (i.e., increasing sensitivity to adrenergic stimulation) [<xref rid="pone.0176446.ref022" ref-type="bibr">22</xref>]. Our studies in postmenopausal human tissue further suggest that E<sub>2</sub> impacts adipose tissue lipolysis via increased EC<sub>50</sub> for glycerol (i.e., increasing sensitivity to insulin stimulation). Future studies are needed to determine whether such E<sub>2</sub>-mediated improvements in lipolytic sensitivity play a role in adipose tissue accrual and function. Moreover, given the relative importance of well-functioning adipose tissue on metabolic health [<xref rid="pone.0176446.ref023" ref-type="bibr">23</xref>], it would be useful to know whether E<sub>2</sub>-mediated improvements on whole body glucoregulatory insulin sensitivity are secondary to improvements in adipose tissue lipolytic sensitivity.</p></sec><sec id="sec027"><title>Potential limitations</title><p>There are some limitations in the current study that should be considered. First, we used the EC<sub>50</sub>, or insulin concentration to half-maximally suppress lipolysis (glycerol), as an index of adipose tissue insulin sensitivity. The measures of insulin and glycerol are done at the whole body level rather than at the tissue level, so the source of glycerol is not exclusively from adipose tissue. However, the contribution of glycerol from muscle and liver is negligible [<xref rid="pone.0176446.ref024" ref-type="bibr">24</xref>] and the systemic measurement of lipolysis is preferable to in vitro where it is difficult to precisely replicate the in vivo insulin and estrogen conditions. Second, in the present study we only collected adipose tissue form the femoral depot, so we did not have abdominal adipose tissue for comparison. Our previous studies suggest there are not depot (abdominal vs. femoral) differences in adipose tissue sensitivity to insulin suppression of lipolysis in postmenopausal women [<xref rid="pone.0176446.ref025" ref-type="bibr">25</xref>]. Nevertheless, there may have been depot differences in ER expression that may have impacted our results. Third, this is a follow-up study to analyze tissues obtained from a larger trial which was powered to detect group differences in E<sub>2</sub>-mediated alterations in whole body glucose disposal; thus the variables reported herein were not statistically powered <italic>a priori</italic>. Fourth, we detected Lamin (nuclear protein marker; <xref ref-type="supplementary-material" rid="pone.0176446.s001">S1 Fig</xref>) in the cytosolic fraction from a number of our SAT samples, suggesting our cytosolic fractions had nuclear contamination possibly due to the freezing process. However, we did not find &#x003b1;-Tubulin (cytosolic protein marker; <xref ref-type="fig" rid="pone.0176446.g001">Fig 1</xref>) in the nuclear fraction so these samples were pure, giving us confidence in our nuclear ER protein results.</p></sec><sec id="sec028"><title>Conclusions</title><p>Our data suggest that there is not an inevitable decline in adipose tissue ER&#x003b1; and ER&#x003b2; protein with increasing age or duration of estrogen deficiency. Compared to placebo, one week of transdermal E<sub>2</sub> improved adipose tissue insulin sensitivity (i.e., less insulin needed to suppress lipolysis) in postmenopausal women, particularly in those women who had a greater proportion of ER&#x003b1;/ER&#x003b2; in adipose tissue. Additional well-controlled human studies are needed to determine the mechanism by which the balance of ER&#x003b1;/ER&#x003b2; impacts the physiologic action of E<sub>2</sub> in all estrogen-responsive tissues.</p></sec></sec><sec sec-type="supplementary-material" id="sec029"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0176446.s001"><label>S1 Fig</label><caption><title>Nuclear protein marker in nuclear and cytosolic fraction.</title><p>(PPTX)</p></caption><media xlink:href="pone.0176446.s001.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank the staffs of the University of Colorado Anschutz Medical Campus Clinical Translational Research Center, and Energy Balance Core of the Colorado Nutrition and Obesity Research Unit for their assistance in conducting this study.</p></ack><ref-list><title>References</title><ref id="pone.0176446.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Carr</surname><given-names>M.C.</given-names></name>, <article-title>The emergence of the metabolic syndrome with menopause</article-title>. <source>J Clin Endocrinol Metab</source>, <year>2003</year>
<volume>88</volume>(<issue>6</issue>): p. <fpage>2404</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jc.2003-030242">10.1210/jc.2003-030242</ext-link></comment>
<pub-id pub-id-type="pmid">12788835</pub-id></mixed-citation></ref><ref id="pone.0176446.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Salpeter</surname><given-names>S.R.</given-names></name>, <name><surname>Walsh</surname><given-names>J.M.</given-names></name>, <name><surname>Ormiston</surname><given-names>T.M.</given-names></name>, <name><surname>Greyber</surname><given-names>E.</given-names></name>, <name><surname>Buckley</surname><given-names>N.S.</given-names></name> and <name><surname>Salpeter</surname><given-names>E.E.</given-names></name>, <article-title>Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women</article-title>. <source>Diabetes Obes Metab</source>, <year>2006</year>
<volume>8</volume>(<issue>5</issue>): p. <fpage>538</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1463-1326.2005.00545.x">10.1111/j.1463-1326.2005.00545.x</ext-link></comment>
<pub-id pub-id-type="pmid">16918589</pub-id></mixed-citation></ref><ref id="pone.0176446.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Van Pelt</surname><given-names>R.E.</given-names></name>, <name><surname>Gozansky</surname><given-names>W.S.</given-names></name>, <name><surname>Schwartz</surname><given-names>R.S.</given-names></name> and <name><surname>Kohrt</surname><given-names>W.M.</given-names></name>, <article-title>Intravenous estrogens increase insulin clearance and action in postmenopausal women</article-title>. <source>Am J Physiol Endocrinol Metab</source>, <year>2003</year>
<volume>285</volume>(<issue>2</issue>): p. <fpage>E311</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpendo.00490.2002">10.1152/ajpendo.00490.2002</ext-link></comment>
<pub-id pub-id-type="pmid">12684221</pub-id></mixed-citation></ref><ref id="pone.0176446.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Van Pelt</surname><given-names>R.E.</given-names></name>, <name><surname>Schwartz</surname><given-names>R.S.</given-names></name> and <name><surname>Kohrt</surname><given-names>W.M.</given-names></name>, <article-title>Insulin secretion and clearance after subacute estradiol administration in postmenopausal women</article-title>. <source>Journal of Clinical Endocrinology and Metabolism</source>, <year>2008</year>
<volume>93</volume>(<issue>2</issue>): p. <fpage>484</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jc.2007-1657">10.1210/jc.2007-1657</ext-link></comment>
<pub-id pub-id-type="pmid">17986638</pub-id></mixed-citation></ref><ref id="pone.0176446.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Pereira</surname><given-names>R.I.</given-names></name>, <name><surname>Casey</surname><given-names>B.A.</given-names></name>, <name><surname>Swibas</surname><given-names>T.A.</given-names></name>, <name><surname>Erickson</surname><given-names>C.B.</given-names></name>, <name><surname>Wolfe</surname><given-names>P.</given-names></name> and <name><surname>Van Pelt</surname><given-names>R.E.</given-names></name>, <article-title>Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action</article-title>. <source>J Clin Endocrinol Metab</source>, <year>2015</year>
<volume>100</volume>(<issue>12</issue>): p. <fpage>4456</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jc.2015-3084">10.1210/jc.2015-3084</ext-link></comment>
<pub-id pub-id-type="pmid">26425886</pub-id></mixed-citation></ref><ref id="pone.0176446.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Dieudonne</surname><given-names>M.N.</given-names></name>, <name><surname>Leneveu</surname><given-names>M.C.</given-names></name>, <name><surname>Giudicelli</surname><given-names>Y.</given-names></name> and <name><surname>Pecquery</surname><given-names>R.</given-names></name>, <article-title>Evidence for functional estrogen receptors alpha and beta in human adipose cells: regional specificities and regulation by estrogens</article-title>. <source>Am J Physiol Cell Physiol</source>, <year>2004</year>
<volume>286</volume>(<issue>3</issue>): p. <fpage>C655</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpcell.00321.2003">10.1152/ajpcell.00321.2003</ext-link></comment>
<pub-id pub-id-type="pmid">14761887</pub-id></mixed-citation></ref><ref id="pone.0176446.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Ribas</surname><given-names>V.</given-names></name>, <name><surname>Nguyen</surname><given-names>M.T.</given-names></name>, <name><surname>Henstridge</surname><given-names>D.C.</given-names></name>, <name><surname>Nguyen</surname><given-names>A.K.</given-names></name>, <name><surname>Beaven</surname><given-names>S.W.</given-names></name>, <name><surname>Watt</surname><given-names>M.J.</given-names></name>, <etal>et al</etal>, <article-title>Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice</article-title>. <source>Am J Physiol Endocrinol Metab</source>, <year>2010</year>
<volume>298</volume>(<issue>2</issue>): p. <fpage>E304</fpage>&#x02013;<lpage>19</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpendo.00504.2009">10.1152/ajpendo.00504.2009</ext-link></comment>
<pub-id pub-id-type="pmid">19920214</pub-id></mixed-citation></ref><ref id="pone.0176446.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Bryzgalova</surname><given-names>G.</given-names></name>, <name><surname>Gao</surname><given-names>H.</given-names></name>, <name><surname>Ahren</surname><given-names>B.</given-names></name>, <name><surname>Zierath</surname><given-names>J.R.</given-names></name>, <name><surname>Galuska</surname><given-names>D.</given-names></name>, <name><surname>Steiler</surname><given-names>T.L.</given-names></name>, <etal>et al</etal>, <article-title>Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver</article-title>. <source>Diabetologia</source>, <year>2006</year>
<volume>49</volume>(<issue>3</issue>): p. <fpage>588</fpage>&#x02013;<lpage>97</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00125-005-0105-3">10.1007/s00125-005-0105-3</ext-link></comment>
<pub-id pub-id-type="pmid">16463047</pub-id></mixed-citation></ref><ref id="pone.0176446.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Barros</surname><given-names>R.P.</given-names></name>, <name><surname>Machado</surname><given-names>U.F.</given-names></name> and <name><surname>Gustafsson</surname><given-names>J.A.</given-names></name>, <article-title>Estrogen receptors: new players in diabetes mellitus</article-title>. <source>Trends Mol Med</source>, <year>2006</year>
<volume>12</volume>(<issue>9</issue>): p. <fpage>425</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molmed.2006.07.004">10.1016/j.molmed.2006.07.004</ext-link></comment>
<pub-id pub-id-type="pmid">16890492</pub-id></mixed-citation></ref><ref id="pone.0176446.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Hevener</surname><given-names>A.L.</given-names></name>, <name><surname>Clegg</surname><given-names>D.J.</given-names></name> and <name><surname>Mauvais-Jarvis</surname><given-names>F.</given-names></name>, <article-title>Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome</article-title>. <source>Mol Cell Endocrinol</source>, <year>2015</year>
<volume>418</volume>
<issue>Pt 3</issue>: p. <fpage>306</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">26033249</pub-id></mixed-citation></ref><ref id="pone.0176446.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>Y.M.</given-names></name>, <name><surname>Pereira</surname><given-names>R.I.</given-names></name>, <name><surname>Erickson</surname><given-names>C.B.</given-names></name>, <name><surname>Swibas</surname><given-names>T.A.</given-names></name>, <name><surname>Kang</surname><given-names>C.</given-names></name> and <name><surname>Van Pelt</surname><given-names>R.E.</given-names></name>, <article-title>Time since menopause and skeletal muscle estrogen receptors, PGC-1alpha, and AMPK</article-title>. <source>Menopause</source>, <year>2017</year>.</mixed-citation></ref><ref id="pone.0176446.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Van Pelt</surname><given-names>R.E.</given-names></name>, <name><surname>Evans</surname><given-names>E.M.</given-names></name>, <name><surname>Schechtman</surname><given-names>K.B.</given-names></name>, <name><surname>Ehsani</surname><given-names>A.A.</given-names></name> and <name><surname>Kohrt</surname><given-names>W.M.</given-names></name>, <article-title>Contributions of total and regional fat mass to risk for cardiovascular disease in older women</article-title>. <source>Am J Physiol Endocrinol Metab</source>, <year>2002</year>
<volume>282</volume>(<issue>5</issue>): p. <fpage>E1023</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpendo.00467.2001">10.1152/ajpendo.00467.2001</ext-link></comment>
<pub-id pub-id-type="pmid">11934666</pub-id></mixed-citation></ref><ref id="pone.0176446.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Stumvoll</surname><given-names>M.</given-names></name>, <name><surname>Jacob</surname><given-names>S.</given-names></name>, <name><surname>Wahl</surname><given-names>H.G.</given-names></name>, <name><surname>Hauer</surname><given-names>B.</given-names></name>, <name><surname>Loblein</surname><given-names>K.</given-names></name>, <name><surname>Grauer</surname><given-names>P.</given-names></name>, <etal>et al</etal>, <article-title>Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans</article-title>. <source>Journal of Clinical Endocrinology and Metabolism</source>, <year>2000</year>
<volume>85</volume>(<issue>10</issue>): p. <fpage>3740</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jcem.85.10.6898">10.1210/jcem.85.10.6898</ext-link></comment>
<pub-id pub-id-type="pmid">11061533</pub-id></mixed-citation></ref><ref id="pone.0176446.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Jackman</surname><given-names>M.R.</given-names></name>, <name><surname>Steig</surname><given-names>A.</given-names></name>, <name><surname>Higgins</surname><given-names>J.A.</given-names></name>, <name><surname>Johnson</surname><given-names>G.C.</given-names></name>, <name><surname>Fleming-Elder</surname><given-names>B.K.</given-names></name>, <name><surname>Bessesen</surname><given-names>D.H.</given-names></name>, <etal>et al</etal>, <article-title>Weight regain after sustained weight reduction is accompanied by suppressed oxidation of dietary fat and adipocyte hyperplasia</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>, <year>2008</year>
<volume>294</volume>(<issue>4</issue>): p. <fpage>R1117</fpage>&#x02013;<lpage>29</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpregu.00808.2007">10.1152/ajpregu.00808.2007</ext-link></comment>
<pub-id pub-id-type="pmid">18287221</pub-id></mixed-citation></ref><ref id="pone.0176446.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Livak</surname><given-names>K.J.</given-names></name> and <name><surname>Schmittgen</surname><given-names>T.D.</given-names></name>, <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title>. <source>Methods</source>, <year>2001</year>
<volume>25</volume>(<issue>4</issue>): p. <fpage>402</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1006/meth.2001.1262">10.1006/meth.2001.1262</ext-link></comment>
<pub-id pub-id-type="pmid">11846609</pub-id></mixed-citation></ref><ref id="pone.0176446.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Pedersen</surname><given-names>S.B.</given-names></name>, <name><surname>Bruun</surname><given-names>J.M.</given-names></name>, <name><surname>Hube</surname><given-names>F.</given-names></name>, <name><surname>Kristensen</surname><given-names>K.</given-names></name>, <name><surname>Hauner</surname><given-names>H.</given-names></name> and <name><surname>Richelsen</surname><given-names>B.</given-names></name>, <article-title>Demonstration of estrogen receptor subtypes alpha and beta in human adipose tissue: influences of adipose cell differentiation and fat depot localization</article-title>. <source>Mol Cell Endocrinol</source>, <year>2001</year>
<volume>182</volume>(<issue>1</issue>): p. <fpage>27</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="pmid">11500236</pub-id></mixed-citation></ref><ref id="pone.0176446.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Barros</surname><given-names>R.P.</given-names></name> and <name><surname>Gustafsson</surname><given-names>J.A.</given-names></name>, <article-title>Estrogen receptors and the metabolic network</article-title>. <source>Cell metabolism</source>, <year>2011</year>
<volume>14</volume>(<issue>3</issue>): p. <fpage>289</fpage>&#x02013;<lpage>99</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cmet.2011.08.005">10.1016/j.cmet.2011.08.005</ext-link></comment>
<pub-id pub-id-type="pmid">21907136</pub-id></mixed-citation></ref><ref id="pone.0176446.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Davis</surname><given-names>K.E.</given-names></name>, <name><surname>D.N.</surname><given-names>M</given-names></name>, <name><surname>Sun</surname><given-names>K.</given-names></name>, <name><surname>M.S.</surname><given-names>W</given-names></name>, <name><surname>D.B.</surname><given-names>J</given-names></name>, <name><surname>A.Z.</surname><given-names>J</given-names></name>, <etal>et al</etal>, <article-title>The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion</article-title>, <article-title>inflammation, and fibrosis</article-title>. <source>Mol Metab</source>, <year>2013</year>
<volume>2</volume>(<issue>3</issue>): p. <fpage>227</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molmet.2013.05.006">10.1016/j.molmet.2013.05.006</ext-link></comment>
</mixed-citation></ref><ref id="pone.0176446.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>McInnes</surname><given-names>K.J.</given-names></name>, <name><surname>Andersson</surname><given-names>T.C.</given-names></name>, <name><surname>Simonyte</surname><given-names>K.</given-names></name>, <name><surname>Soderstrom</surname><given-names>I.</given-names></name>, <name><surname>Mattsson</surname><given-names>C.</given-names></name>, <name><surname>Seckl</surname><given-names>J.R.</given-names></name>, <etal>et al</etal>, <article-title>Association of 11beta-hydroxysteroid dehydrogenase type I expression and activity with estrogen receptor beta in adipose tissue from postmenopausal women</article-title>. <source>Menopause</source>, <year>2012</year>
<volume>19</volume>(<issue>12</issue>): p. <fpage>1347</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/gme.0b013e318258aad7">10.1097/gme.0b013e318258aad7</ext-link></comment>
<pub-id pub-id-type="pmid">23190557</pub-id></mixed-citation></ref><ref id="pone.0176446.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Fernandez-Marcos</surname><given-names>P.J.</given-names></name> and <name><surname>Auwerx</surname><given-names>J.</given-names></name>, <article-title>Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis</article-title>. <source>Am J Clin Nutr</source>, <year>2011</year>
<volume>93</volume>(<issue>4</issue>): p. <fpage>884S</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3945/ajcn.110.001917">10.3945/ajcn.110.001917</ext-link></comment>
<pub-id pub-id-type="pmid">21289221</pub-id></mixed-citation></ref><ref id="pone.0176446.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Barros</surname><given-names>R.P.</given-names></name>, <name><surname>Gabbi</surname><given-names>C.</given-names></name>, <name><surname>Morani</surname><given-names>A.</given-names></name>, <name><surname>Warner</surname><given-names>M.</given-names></name> and <name><surname>Gustafsson</surname><given-names>J.A.</given-names></name>, <article-title>Participation of ERalpha and ERbeta in glucose homeostasis in skeletal muscle and white adipose tissue</article-title>. <source>Am J Physiol Endocrinol Metab</source>, <year>2009</year>
<volume>297</volume>(<issue>1</issue>): p. <fpage>E124</fpage>&#x02013;<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpendo.00189.2009">10.1152/ajpendo.00189.2009</ext-link></comment>
<pub-id pub-id-type="pmid">19366879</pub-id></mixed-citation></ref><ref id="pone.0176446.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Pedersen</surname><given-names>S.B.</given-names></name>, <name><surname>Kristensen</surname><given-names>K.</given-names></name>, <name><surname>Hermann</surname><given-names>P.A.</given-names></name>, <name><surname>Katzenellenbogen</surname><given-names>J.A.</given-names></name> and <name><surname>Richelsen</surname><given-names>B.</given-names></name>, <article-title>Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution</article-title>. <source>J Clin Endocrinol Metab</source>, <year>2004</year>
<volume>89</volume>(<issue>4</issue>): p. <fpage>1869</fpage>&#x02013;<lpage>78</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1210/jc.2003-031327">10.1210/jc.2003-031327</ext-link></comment>
<pub-id pub-id-type="pmid">15070958</pub-id></mixed-citation></ref><ref id="pone.0176446.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Morley</surname><given-names>T.S.</given-names></name>, <name><surname>Xia</surname><given-names>J.Y.</given-names></name> and <name><surname>Scherer</surname><given-names>P.E.</given-names></name>, <article-title>Selective enhancement of insulin sensitivity in the mature adipocyte is sufficient for systemic metabolic improvements</article-title>. <source>Nat Commun</source>, <year>2015</year>
<volume>6</volume>: p. <fpage>7906</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ncomms8906">10.1038/ncomms8906</ext-link></comment>
<pub-id pub-id-type="pmid">26243466</pub-id></mixed-citation></ref><ref id="pone.0176446.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Coppack</surname><given-names>S.W.</given-names></name>, <name><surname>Persson</surname><given-names>M.</given-names></name>, <name><surname>Judd</surname><given-names>R.L.</given-names></name> and <name><surname>Miles</surname><given-names>J.M.</given-names></name>, <article-title>Glycerol and nonesterified fatty acid metabolism in human muscle and adipose tissue in vivo</article-title>. <source>Am J Physiol</source>, <year>1999</year>
<volume>276</volume>(<issue>2 Pt 1</issue>): p. <fpage>E233</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="pmid">9950781</pub-id></mixed-citation></ref><ref id="pone.0176446.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Van Pelt</surname><given-names>R.E.</given-names></name>, <name><surname>Gozansky</surname><given-names>W.S.</given-names></name>, <name><surname>Hickner</surname><given-names>R.C.</given-names></name>, <name><surname>Schwartz</surname><given-names>R.S.</given-names></name> and <name><surname>Kohrt</surname><given-names>W.M.</given-names></name>, <article-title>Acute modulation of adipose tissue lipolysis by intravenous estrogens</article-title>. <source>Obesity (Silver Spring)</source>, <year>2006</year>
<volume>14</volume>(<issue>12</issue>): p. <fpage>2163</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">17189542</pub-id></mixed-citation></ref></ref-list></back></article>